Celgene nabs FDA approval for blockbuster hopeful anemia med Reblozyl Bristol-Myers Squibb’s $74 billion pending pick-up of Celgene has notched a win already with an FDA approval for JAK med […]
Pfizer’s ‘brainstorming’ payment deals as gene therapies advance, exec tells Bloomberg Gene therapies offer a “world of wonders” for patients, but they present some scientific and manufacturing challenges, a top […]
AbbVie unveils Venclexta data that scored lightning-fast leukemia combination nod Last month, partners AbbVie and Roche nabbed a speedy approval for Venclexta and Gazyva in chronic lymphocytic leukemia. And Tuesday, […]
Lilly’s scored its cluster headache nod for Emgality. Will it shake up the CGRP race? Eli Lilly’s Emgality didn’t just hit the next-gen migraine market in third place behind Amgen’s […]
Express Scripts bars 48 drugs for 2019, hitting AbbVie, Gilead, Boehringer and more It’s that time of year again—the time when lead pharmacy benefits manager Express Scripts ignites pharma’s ire […]